What is the appropriate dosing of polyethylene glycol (MiraLAX) for patients with renal impairment, including adults and children?

MiraLAX Renal Dosing

No dose adjustment is required for polyethylene glycol 3350 (MiraLAX) in patients with renal impairment, including those on dialysis, as the medication is minimally absorbed systemically and primarily eliminated via feces.

Pharmacokinetic Rationale

Polyethylene glycol 3350 has favorable pharmacokinetics that make it safe in renal impairment 1:

• Minimal systemic absorption: Only 0.19-0.25% of the administered dose is excreted in urine
• Primary fecal elimination: Approximately 93% of the dose is eliminated unchanged in feces
• Rapid clearance: Peak plasma concentrations occur at 2-4 hours with a half-life of 4-6 hours
• No accumulation: Renal impairment (including mild kidney impairment) does not alter PEG-3350 pharmacokinetics

Standard Dosing Across Renal Function

Adults

• Standard dose: 17 grams (1 capful) once daily 2, 3
• No maximum dose clearly defined, but titrate based on symptom response and tolerability
• This applies to all levels of renal function, including dialysis patients

Children

• Infants < 18 months: 0.78 g/kg/day (mean effective maintenance dose) 4
• Children ≥ 18 months: 0.5-1.5 g/kg/day, typically starting at lower end and titrating up

Evidence in Dialysis Patients

A prospective case series specifically evaluated PEG-3350 in hemodialysis patients 5:

• Successfully reduced need for stimulant laxatives
• Increased spontaneous bowel movements with ideal stool consistency
• No serious adverse effects observed
• Demonstrated both efficacy and safety in this population

Important Safety Considerations

Monitor for Dehydration-Related AKI

While PEG-3350 itself requires no dose adjustment, be aware of indirect renal risks:

• Osmotic diarrhea can lead to volume depletion and pre-renal azotemia 6, 7
• Ensure adequate hydration, especially in patients with baseline renal impairment
• Risk is higher with excessive doses or prolonged misuse 7

Avoid Concurrent Nephrotoxic Agents

• NSAIDs combined with PEG use increase AKI risk (OR 6.5) 6
• Exercise caution with other nephrotoxic medications

Electrolyte Monitoring

• Standard PEG-3350 (MiraLAX) does not contain electrolytes
• In patients with advanced CKD or on dialysis, monitor for electrolyte disturbances if diarrhea occurs
• Consider switching to PEG formulations with electrolytes if prolonged use is needed in dialysis patients 5

Common Pitfalls to Avoid

1. Do not reduce the dose based solely on renal function—this is unnecessary and may reduce efficacy
2. Do not confuse with other PEG-containing medications (e.g., IV methocarbamol) that have different toxicity profiles 8
3. Do not overlook volume status—the main renal risk is indirect through dehydration, not direct nephrotoxicity
4. Ensure adequate fluid intake as fiber and osmotic laxatives require hydration to work effectively 2

Practical Dosing Guidance

For patients with any degree of renal impairment:

• Start with standard adult dose of 17 grams daily
• Titrate based on stool consistency and frequency, not renal function
• Common side effects (bloating, cramping) are dose-related but not influenced by kidney function
• Response is typically seen within 1-3 days

For dialysis patients specifically:

• No timing adjustment needed relative to dialysis sessions (unlike renally-cleared medications)
• PEG-3350 with electrolytes may be preferable for long-term use 5